Pfiz­er’s PhI­II kid­ney can­cer study for In­ly­ta flops as in­ves­ti­ga­tors flag a dead end on out­comes

Pfiz­er has lost out on a Phase III bid to re­vive flag­ging sales of its VEGF in­hibitor In­ly­ta (ax­i­tinib). 

Re­searchers say their drug, ini­tial­ly ap­proved as a sec­ond-line kid­ney can­cer drug 6 years ago, failed to make a fa­vor­able im­pact on pa­tients at high risk of re­cur­ring kid­ney can­cer, un­able to beat out a place­bo for main­tain­ing dis­ease-free rates. The tri­al was stopped af­ter in­de­pen­dent mon­i­tors called it on clear ev­i­dence of fu­til­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER